JPH10508311A - スピロ[複素環−イミダゾ[1,2−a]インデノ[1,2−e]ピラジン]−4’−オン類、これらの調製、及びこれらを含んでいる医薬品 - Google Patents
スピロ[複素環−イミダゾ[1,2−a]インデノ[1,2−e]ピラジン]−4’−オン類、これらの調製、及びこれらを含んでいる医薬品Info
- Publication number
- JPH10508311A JPH10508311A JP8515088A JP51508896A JPH10508311A JP H10508311 A JPH10508311 A JP H10508311A JP 8515088 A JP8515088 A JP 8515088A JP 51508896 A JP51508896 A JP 51508896A JP H10508311 A JPH10508311 A JP H10508311A
- Authority
- JP
- Japan
- Prior art keywords
- alk
- ring
- group
- formula
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 title claims description 126
- 125000003003 spiro group Chemical group 0.000 title claims description 29
- 239000003814 drug Substances 0.000 title claims description 9
- 238000002360 preparation method Methods 0.000 title claims description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 90
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 88
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 87
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 58
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical group C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 claims abstract description 35
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 17
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 15
- 239000005557 antagonist Substances 0.000 claims abstract description 6
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 claims abstract description 5
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 claims abstract description 5
- 125000003386 piperidinyl group Chemical group 0.000 claims abstract description 3
- -1 cyano, phenyl Chemical group 0.000 claims description 54
- 150000001721 carbon Chemical group 0.000 claims description 44
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 44
- FUFZNHHSSMCXCZ-UHFFFAOYSA-N 5-piperidin-4-yl-3-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazole Chemical group FC(F)(F)C1=CC=CC(C=2N=C(ON=2)C2CCNCC2)=C1 FUFZNHHSSMCXCZ-UHFFFAOYSA-N 0.000 claims description 42
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims description 37
- 229910052757 nitrogen Inorganic materials 0.000 claims description 35
- 150000003839 salts Chemical class 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 34
- 239000002253 acid Substances 0.000 claims description 31
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 27
- 238000006243 chemical reaction Methods 0.000 claims description 24
- 125000005843 halogen group Chemical group 0.000 claims description 24
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 21
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 20
- 125000003884 phenylalkyl group Chemical group 0.000 claims description 19
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 18
- 125000003545 alkoxy group Chemical group 0.000 claims description 13
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 13
- 125000006239 protecting group Chemical group 0.000 claims description 11
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 10
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 10
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 10
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 9
- 239000001257 hydrogen Substances 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- 125000001424 substituent group Chemical group 0.000 claims description 7
- 150000001412 amines Chemical group 0.000 claims description 6
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 5
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 5
- 229910052786 argon Inorganic materials 0.000 claims description 5
- 239000004020 conductor Substances 0.000 claims description 5
- 235000019253 formic acid Nutrition 0.000 claims description 5
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 claims description 5
- 239000012279 sodium borohydride Substances 0.000 claims description 5
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 5
- 125000004429 atom Chemical group 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 150000004820 halides Chemical class 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 3
- 125000002947 alkylene group Chemical group 0.000 claims description 3
- 150000008064 anhydrides Chemical class 0.000 claims description 3
- 125000005392 carboxamide group Chemical group NC(=O)* 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 125000002883 imidazolyl group Chemical group 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- 229920006395 saturated elastomer Polymers 0.000 claims description 3
- 125000000565 sulfonamide group Chemical group 0.000 claims description 3
- GYPCWHHQAVLMKO-XXKQIVDLSA-N (7s,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-[(e)-n-[(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-ylidene)amino]-c-methylcarbonimidoyl]-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical group Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\N=C1CC(C)(C)N(O)C(C)(C)C1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 GYPCWHHQAVLMKO-XXKQIVDLSA-N 0.000 claims description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- 102000003678 AMPA Receptors Human genes 0.000 claims description 2
- 108090000078 AMPA Receptors Proteins 0.000 claims description 2
- 239000012190 activator Substances 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims description 2
- 239000012948 isocyanate Substances 0.000 claims description 2
- KQEVIFKPZOGBMZ-UHFFFAOYSA-N methyl 3-bromopropanoate Chemical compound COC(=O)CCBr KQEVIFKPZOGBMZ-UHFFFAOYSA-N 0.000 claims description 2
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims description 2
- 125000005968 oxazolinyl group Chemical group 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 125000005543 phthalimide group Chemical group 0.000 claims description 2
- 125000004585 polycyclic heterocycle group Chemical group 0.000 claims description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 2
- 229910052702 rhenium Inorganic materials 0.000 claims description 2
- 125000004434 sulfur atom Chemical group 0.000 claims description 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 6
- CZTQZXZIADLWOZ-CRAIPNDOSA-N cefaloridine Chemical group O=C([C@@H](NC(=O)CC=1SC=CC=1)[C@H]1SC2)N1C(C(=O)[O-])=C2C[N+]1=CC=CC=C1 CZTQZXZIADLWOZ-CRAIPNDOSA-N 0.000 claims 5
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- VEQOALNAAJBPNY-UHFFFAOYSA-N antipyrine Chemical compound CN1C(C)=CC(=O)N1C1=CC=CC=C1 VEQOALNAAJBPNY-UHFFFAOYSA-N 0.000 claims 1
- 229920001577 copolymer Chemical group 0.000 claims 1
- PTVBBIMKLOMGSY-UHFFFAOYSA-N n,n-bis(2-chloroethyl)-4-methylbenzenesulfonamide Chemical compound CC1=CC=C(S(=O)(=O)N(CCCl)CCCl)C=C1 PTVBBIMKLOMGSY-UHFFFAOYSA-N 0.000 claims 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical group CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 229960005222 phenazone Drugs 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract description 8
- 102000005962 receptors Human genes 0.000 abstract description 7
- 108020003175 receptors Proteins 0.000 abstract description 7
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 abstract description 5
- 239000004471 Glycine Substances 0.000 abstract description 4
- 239000003446 ligand Substances 0.000 abstract description 2
- 230000000144 pharmacologic effect Effects 0.000 abstract description 2
- UUDAMDVQRQNNHZ-UHFFFAOYSA-N (S)-AMPA Chemical compound CC=1ONC(=O)C=1CC(N)C(O)=O UUDAMDVQRQNNHZ-UHFFFAOYSA-N 0.000 abstract 2
- ASNFTDCKZKHJSW-UHFFFAOYSA-N DL-Quisqualic acid Natural products OC(=O)C(N)CN1OC(=O)NC1=O ASNFTDCKZKHJSW-UHFFFAOYSA-N 0.000 abstract 1
- ASNFTDCKZKHJSW-REOHCLBHSA-N Quisqualic acid Chemical compound OC(=O)[C@@H](N)CN1OC(=O)NC1=O ASNFTDCKZKHJSW-REOHCLBHSA-N 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 114
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 97
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 81
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 60
- 239000007787 solid Substances 0.000 description 59
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 57
- 239000000203 mixture Substances 0.000 description 57
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 51
- 239000012153 distilled water Substances 0.000 description 49
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 45
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 39
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 38
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 35
- 239000012429 reaction media Substances 0.000 description 35
- 238000009835 boiling Methods 0.000 description 33
- 238000003756 stirring Methods 0.000 description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 32
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 31
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 29
- 239000000243 solution Substances 0.000 description 29
- 239000012442 inert solvent Substances 0.000 description 24
- 239000000047 product Substances 0.000 description 24
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 23
- 238000001914 filtration Methods 0.000 description 22
- 230000009471 action Effects 0.000 description 21
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 20
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 20
- 235000011054 acetic acid Nutrition 0.000 description 20
- 239000000725 suspension Substances 0.000 description 20
- 239000011541 reaction mixture Substances 0.000 description 17
- 238000002844 melting Methods 0.000 description 16
- 230000008018 melting Effects 0.000 description 16
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 15
- 239000000155 melt Substances 0.000 description 15
- 239000000377 silicon dioxide Substances 0.000 description 15
- 230000006978 adaptation Effects 0.000 description 14
- 238000004587 chromatography analysis Methods 0.000 description 14
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 12
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 12
- 238000001704 evaporation Methods 0.000 description 12
- 230000008020 evaporation Effects 0.000 description 12
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 12
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 11
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 11
- 238000001035 drying Methods 0.000 description 11
- 239000000706 filtrate Substances 0.000 description 11
- 230000007062 hydrolysis Effects 0.000 description 11
- 238000006460 hydrolysis reaction Methods 0.000 description 11
- 239000012312 sodium hydride Substances 0.000 description 11
- 229910000104 sodium hydride Inorganic materials 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 10
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- 229910052783 alkali metal Inorganic materials 0.000 description 10
- 229960001701 chloroform Drugs 0.000 description 10
- 239000002244 precipitate Substances 0.000 description 10
- 150000001340 alkali metals Chemical class 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 239000003610 charcoal Substances 0.000 description 9
- 239000012043 crude product Substances 0.000 description 9
- 238000010992 reflux Methods 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000006196 drop Substances 0.000 description 8
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 7
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 7
- 235000011114 ammonium hydroxide Nutrition 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 239000003480 eluent Substances 0.000 description 7
- 239000002198 insoluble material Substances 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- ATHHXGZTWNVVOU-UHFFFAOYSA-N N-methylformamide Chemical compound CNC=O ATHHXGZTWNVVOU-UHFFFAOYSA-N 0.000 description 6
- 150000007513 acids Chemical class 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 238000007363 ring formation reaction Methods 0.000 description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 5
- 239000000460 chlorine Substances 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 238000002425 crystallisation Methods 0.000 description 5
- 230000008025 crystallization Effects 0.000 description 5
- 238000010511 deprotection reaction Methods 0.000 description 5
- 125000000623 heterocyclic group Chemical group 0.000 description 5
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- 125000005270 trialkylamine group Chemical group 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- WDAQGVJSNJRSFQ-UHFFFAOYSA-N 9h-indeno[1,2-b]pyrazine Chemical compound C1=CN=C2CC3=CC=CC=C3C2=N1 WDAQGVJSNJRSFQ-UHFFFAOYSA-N 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 150000007530 organic bases Chemical class 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 125000002734 organomagnesium group Chemical class 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- SEPPVOUBHWNCAW-FNORWQNLSA-N (E)-4-oxonon-2-enal Chemical compound CCCCCC(=O)\C=C\C=O SEPPVOUBHWNCAW-FNORWQNLSA-N 0.000 description 3
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 3
- LLBZPESJRQGYMB-UHFFFAOYSA-N 4-one Natural products O1C(C(=O)CC)CC(C)C11C2(C)CCC(C3(C)C(C(C)(CO)C(OC4C(C(O)C(O)C(COC5C(C(O)C(O)CO5)OC5C(C(OC6C(C(O)C(O)C(CO)O6)O)C(O)C(CO)O5)OC5C(C(O)C(O)C(C)O5)O)O4)O)CC3)CC3)=C3C2(C)CC1 LLBZPESJRQGYMB-UHFFFAOYSA-N 0.000 description 3
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 3
- 241001443715 Fusarium oxysporum f. sp. conglutinans Species 0.000 description 3
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- 150000001342 alkaline earth metals Chemical class 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 244000309464 bull Species 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000007806 chemical reaction intermediate Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 235000008504 concentrate Nutrition 0.000 description 3
- 238000009833 condensation Methods 0.000 description 3
- 230000005494 condensation Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229910052744 lithium Inorganic materials 0.000 description 3
- HAMGRBXTJNITHG-UHFFFAOYSA-N methyl isocyanate Chemical compound CN=C=O HAMGRBXTJNITHG-UHFFFAOYSA-N 0.000 description 3
- 238000006053 organic reaction Methods 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 3
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- UIKPUVLIJJJXNA-UHFFFAOYSA-N 1-methylimidazole-2-carboxamide Chemical compound CN1C=CN=C1C(N)=O UIKPUVLIJJJXNA-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- JLAKCHGEEBPDQI-UHFFFAOYSA-N 4-(4-fluorobenzyl)piperidine Chemical compound C1=CC(F)=CC=C1CC1CCNCC1 JLAKCHGEEBPDQI-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 208000019932 Aciduria Diseases 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- 241000976983 Anoxia Species 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 206010008027 Cerebellar atrophy Diseases 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 206010012335 Dependence Diseases 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- 208000032274 Encephalopathy Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical compound CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 201000002169 Mitochondrial myopathy Diseases 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010037742 Rabies Diseases 0.000 description 2
- 208000006289 Rett Syndrome Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 206010043376 Tetanus Diseases 0.000 description 2
- 208000000323 Tourette Syndrome Diseases 0.000 description 2
- 208000016620 Tourette disease Diseases 0.000 description 2
- 208000010045 Wernicke encephalopathy Diseases 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000007953 anoxia Effects 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 150000001555 benzenes Chemical class 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 239000008119 colloidal silica Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 150000001913 cyanates Chemical class 0.000 description 2
- 238000006264 debenzylation reaction Methods 0.000 description 2
- ODCCJTMPMUFERV-UHFFFAOYSA-N ditert-butyl carbonate Chemical compound CC(C)(C)OC(=O)OC(C)(C)C ODCCJTMPMUFERV-UHFFFAOYSA-N 0.000 description 2
- 206010013663 drug dependence Diseases 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 230000002140 halogenating effect Effects 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 208000007386 hepatic encephalopathy Diseases 0.000 description 2
- 150000004678 hydrides Chemical class 0.000 description 2
- 208000023692 inborn mitochondrial myopathy Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000002581 neurotoxin Substances 0.000 description 2
- 231100000618 neurotoxin Toxicity 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 125000001979 organolithium group Chemical group 0.000 description 2
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 2
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000011435 rock Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Chemical compound C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- SGUVLZREKBPKCE-UHFFFAOYSA-N 1,5-diazabicyclo[4.3.0]-non-5-ene Chemical compound C1CCN=C2CCCN21 SGUVLZREKBPKCE-UHFFFAOYSA-N 0.000 description 1
- NIDSRGCVYOEDFW-UHFFFAOYSA-N 1-bromo-4-chlorobutane Chemical compound ClCCCCBr NIDSRGCVYOEDFW-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- AORFLOSEDNKGFR-UHFFFAOYSA-N 1-phenyl-N-(silylmethyl)methanamine Chemical compound C1(=CC=CC=C1)CNC[SiH3] AORFLOSEDNKGFR-UHFFFAOYSA-N 0.000 description 1
- FWBQOWUQNVDNQL-UHFFFAOYSA-N 10-hydroxymethyl-5h,10h-imidazo[1,2-a]indeno[1,2-e]pyrazin-4-one Chemical compound N1C(=O)C2=NC=CN2C2=C1C1=CC=CC=C1C2CO FWBQOWUQNVDNQL-UHFFFAOYSA-N 0.000 description 1
- FMGFKMNKVTWWPO-UHFFFAOYSA-N 10-hydroxymethylene-5h,10h-imidazo[1,2-a]indeno-[1,2-e]pyrazin-4-one Chemical compound N1C(=O)C2=NC=CN2C2=C1C1=CC=CC=C1C2=CO FMGFKMNKVTWWPO-UHFFFAOYSA-N 0.000 description 1
- QJXQFMNMJDMGFS-UHFFFAOYSA-N 16-methylidene-2,5,8-triazatetracyclo[7.7.0.02,6.010,15]hexadeca-1(9),3,5,10,12,14-hexaen-7-one Chemical compound N1C(=O)C2=NC=CN2C2=C1C1=CC=CC=C1C2=C QJXQFMNMJDMGFS-UHFFFAOYSA-N 0.000 description 1
- XPISDIOVNAKDHU-UHFFFAOYSA-N 1H-indene hydrobromide Chemical compound C1C=CC2=CC=CC=C12.Br XPISDIOVNAKDHU-UHFFFAOYSA-N 0.000 description 1
- NHZLLKNRTDIFAD-UHFFFAOYSA-N 2,5-dihydro-1,3-oxazole Chemical compound C1OCN=C1 NHZLLKNRTDIFAD-UHFFFAOYSA-N 0.000 description 1
- HCYFGRCYSCXKNQ-UHFFFAOYSA-N 2-(1,3-dimethyl-2,6-dioxo-7-purinyl)acetic acid Chemical compound O=C1N(C)C(=O)N(C)C2=C1N(CC(O)=O)C=N2 HCYFGRCYSCXKNQ-UHFFFAOYSA-N 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- HUHXLHLWASNVDB-UHFFFAOYSA-N 2-(oxan-2-yloxy)oxane Chemical compound O1CCCCC1OC1OCCCC1 HUHXLHLWASNVDB-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- VMZCDNSFRSVYKQ-UHFFFAOYSA-N 2-phenylacetyl chloride Chemical compound ClC(=O)CC1=CC=CC=C1 VMZCDNSFRSVYKQ-UHFFFAOYSA-N 0.000 description 1
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 1
- YSXIJTDOCXJNHI-UHFFFAOYSA-N 3-(1,2-oxazol-4-yl)propanoic acid Chemical compound OC(=O)CCC=1C=NOC=1 YSXIJTDOCXJNHI-UHFFFAOYSA-N 0.000 description 1
- IUNZBFGNHKODEU-UHFFFAOYSA-N 3-(dimethylamino)propanoyl chloride Chemical compound CN(C)CCC(Cl)=O IUNZBFGNHKODEU-UHFFFAOYSA-N 0.000 description 1
- XZBXAYCCBFTQHH-UHFFFAOYSA-N 3-chloropropylbenzene Chemical compound ClCCCC1=CC=CC=C1 XZBXAYCCBFTQHH-UHFFFAOYSA-N 0.000 description 1
- MFEILWXBDBCWKF-UHFFFAOYSA-N 3-phenylpropanoyl chloride Chemical compound ClC(=O)CCC1=CC=CC=C1 MFEILWXBDBCWKF-UHFFFAOYSA-N 0.000 description 1
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- UZFMOKQJFYMBGY-UHFFFAOYSA-N 4-hydroxy-TEMPO Chemical compound CC1(C)CC(O)CC(C)(C)N1[O] UZFMOKQJFYMBGY-UHFFFAOYSA-N 0.000 description 1
- AQQPIVYLMVOXNA-UHFFFAOYSA-N 5h,10h-imidazo-[1,2-a]indeno[1,2-e]pyrazin-4-one Chemical compound C1=CC=C2C(NC(C3=NC=CN33)=O)=C3CC2=C1 AQQPIVYLMVOXNA-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 229940098747 AMPA receptor antagonist Drugs 0.000 description 1
- 239000000775 AMPA receptor antagonist Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000000103 Anorexia Nervosa Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 208000002381 Brain Hypoxia Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 235000001018 Hibiscus sabdariffa Nutrition 0.000 description 1
- 208000033892 Hyperhomocysteinemia Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- MFESCIUQSIBMSM-UHFFFAOYSA-N I-BCP Chemical compound ClCCCBr MFESCIUQSIBMSM-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000021342 Isolated sulfite oxidase deficiency Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 241001553014 Myrsine salicina Species 0.000 description 1
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical group CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 101710138657 Neurotoxin Proteins 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000206607 Porphyra umbilicalis Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 235000005291 Rumex acetosa Nutrition 0.000 description 1
- 240000007001 Rumex acetosella Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 108700036932 Sulfite oxidase deficiency Proteins 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 229910052776 Thorium Inorganic materials 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229950003769 acefylline Drugs 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229940125709 anorectic agent Drugs 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002460 anti-migrenic effect Effects 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 239000002282 antimigraine agent Substances 0.000 description 1
- 229940125684 antimigraine agent Drugs 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
- ZFTFAPZRGNKQPU-UHFFFAOYSA-N dicarbonic acid Chemical compound OC(=O)OC(O)=O ZFTFAPZRGNKQPU-UHFFFAOYSA-N 0.000 description 1
- 150000001993 dienes Chemical class 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 210000003027 ear inner Anatomy 0.000 description 1
- 210000000959 ear middle Anatomy 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000002895 emetic Substances 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- QNXSIUBBGPHDDE-UHFFFAOYSA-N indan-1-one Chemical compound C1=CC=C2C(=O)CCC2=C1 QNXSIUBBGPHDDE-UHFFFAOYSA-N 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- YDNLNVZZTACNJX-UHFFFAOYSA-N isocyanatomethylbenzene Chemical compound O=C=NCC1=CC=CC=C1 YDNLNVZZTACNJX-UHFFFAOYSA-N 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- ACEONLNNWKIPTM-UHFFFAOYSA-N methyl 2-bromopropanoate Chemical compound COC(=O)C(C)Br ACEONLNNWKIPTM-UHFFFAOYSA-N 0.000 description 1
- GTCAXTIRRLKXRU-UHFFFAOYSA-N methyl carbamate Chemical class COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000007625 mitochondrial abnormality Effects 0.000 description 1
- HXRAMSFGUAOAJR-UHFFFAOYSA-N n,n,n',n'-tetramethyl-1-[(2-methylpropan-2-yl)oxy]methanediamine Chemical compound CN(C)C(N(C)C)OC(C)(C)C HXRAMSFGUAOAJR-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- SNMVRZFUUCLYTO-UHFFFAOYSA-N n-propyl chloride Chemical compound CCCCl SNMVRZFUUCLYTO-UHFFFAOYSA-N 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- SOQBVABWOPYFQZ-UHFFFAOYSA-N oxygen(2-);titanium(4+) Chemical class [O-2].[O-2].[Ti+4] SOQBVABWOPYFQZ-UHFFFAOYSA-N 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- DGTNSSLYPYDJGL-UHFFFAOYSA-N phenyl isocyanate Chemical compound O=C=NC1=CC=CC=C1 DGTNSSLYPYDJGL-UHFFFAOYSA-N 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- FYRHIOVKTDQVFC-UHFFFAOYSA-M potassium phthalimide Chemical compound [K+].C1=CC=C2C(=O)[N-]C(=O)C2=C1 FYRHIOVKTDQVFC-UHFFFAOYSA-M 0.000 description 1
- ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 235000003513 sheep sorrel Nutrition 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 235000011044 succinic acid Nutrition 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- HFRXJVQOXRXOPP-UHFFFAOYSA-N thionyl bromide Chemical compound BrS(Br)=O HFRXJVQOXRXOPP-UHFFFAOYSA-N 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- WILBTFWIBAOWLN-UHFFFAOYSA-N triethyl(triethylsilyloxy)silane Chemical compound CC[Si](CC)(CC)O[Si](CC)(CC)CC WILBTFWIBAOWLN-UHFFFAOYSA-N 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/20—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.式、 式中、 - Rは、水素原子、またはカルボキシル、アルコキシカルボニル、もしくはカル ボキサミド基を表し、 - 同一または異なることができるR1及びR2は、水素もしくはハロゲン原子、ま たはアルキル、アルコキシ、アミノ、−N=CH−N(alk)alk’、ニト ロ、シアノ、フェニル、イミダゾリル、SO3H、ヒドロキシル、ポリフルオロ アルコキシ、カルボキシル、アルコキシカルボニル、−NH−CO−NR5R6、 −N(alk)−CO−NR5R6、−N(alk−Ar)−CO−NR5R6、− NH−CS−NR5R6、−N(alk)−CS−NR5R6、−NH−CO−R5 、−NH−CS−R7、−NH−C(=NR9)−NR8R6、−N(alk)−C (=NR9)−NR8R6、−CO−NR8R6、−NH−SO2−NR8R6、−N( alk)−SO2−NR8R6、−NH−SO2−CF3、−NH−SO2−alk、 −NH−SO2−Ar、−NR8R10、−S(O)m−alk−Arもしくは−S O2−NR8R6基、または場合によっては3位においてアルキル基で置換される 2−オキソ−1−イミダゾリジニル基、または場 合によっては3位においてアルキル基で置換される2−オキソペルヒドロ−1− ピリミジニル基を表し、 - R3及びR4は、これらが結合する炭素原子と共に、(a)場合によっては環が その窒素において、アルキル、−CHO、−COOR11、−CO−alk−CO OR6、−CO−alk−NR6R12、−CO−alk−CONR6R8、−CO− COOR6、−CO−CH2−O−CH2−COOR6、−CO−CH2−S−CH2 −COOR6、−CO−CH=CH−COOR6、−CO−alk、−CO−Ar ”、−CO−alk−Ar”、−CO−NH−Ar”、−CO−NH−alk− Ar”、−CO−Het、−CO−alk−Het、−CO−NH−Het、− CO−NH−alk−Het、−CO−NH2、−CO−NH−alk、−CO −N(alk)alk’、−CS−NH2、−CS−NH−alk、−CS−N H−Ar”、−CS−NH−Het、−alk−Het、−alk−NR6R8、 −alk−COOR6、−alk−CO−NR6R8、−alk−Ar”、−SO2 −alkもしくは−SO2−Ar基、またはシクロアルキル基が場合によっては 2位においてカルボキシル基で置換される−CO−シクロアルキル基で置換され る、2−もしくは3−ピロリジン環、2−もしくは4−ピペリジン環、または2 −アザシクロヘプタン環、あるいは(b)2−ピロリジン−5−オン環を形成し 、 - R5は、水素原子もしくはアルキル(直鎖もしくは分枝鎖の1−9C)、−a lk−COOR8、−alk−Hetもしくは−alk−NR6R8基、場合によ ってはハロゲン原子、並びにアルキル、アルコキシ、ニトロ、アミノ、ヒドロキ シル、−alk−NH2、カルボキシル、アルコキシカルボニル、シアノ、及び −alk−COOR8基から選択され る一つまたはそれより多い置換基でフェニル環が置換されるフェニルアルキル基 、場合によってはハロゲン原子並びにアルキル、アルコキシ、ニトロ、アミノ、 ヒドロキシル、−alk−NH2、カルボキシル、アルコキシカルボニル、シア ノ、及び−alk−COOR8基から選択される一つまたはそれより多い置換基 で置換されるフェニル基、または−Het基を表し、 - R6は、水素原子またはアルキル基を表し、 - R7は、アルキルまたはフェニル基を表し、 - R8は、水素原子またはアルキル基を表し、 - R9は、水素原子またはアルキル基を表し、 - R10は、アルキル、Het、またはアルコキシカルボニル基を表し、 - R11は、アルキルまたはフェニルアルキル基を表し、 - R12は、水素原子、またはアルキルもしくは−CO−NH−alk基を表し、 - alkは、アルキルまたはアルキレン基を表し、 - alk’は、アルキル基を表し、 - mは、0、1、または2に等しく、 - Arは、フェニル基を表し、 - Ar”は、フェニル基、またはハロゲン原子、並びにアルキル、アルコキシ、 ニトロ、アミノ、ヒドロキシル、シアノ、−alk−NH2、−COOR6、及び −alk−COOR6基から選択される一つまたはそれより多い置換基で置換さ れたフェニル基であり、 - Hetは、(a)1ないし9個の炭素原子、及び場合によっては一つまたはそ れより多いアルキル、フェニル、カルボキシル、またはフェニ ルアルキル基で置換される一つもまたはそれより多いヘテロ原子(O、S、もし くはN)を含んでいる飽和または不飽和の単または多環式複素環、あるいは(b )フタルイミド基を表し、 別に記載しないかぎり、アルキル、アルキレン、及びアルコキシ基、並びに部分 は、1ないし6個の炭素原子を含み、直鎖または分枝鎖であり、シクロアルキル 基は、3ないし6個の原子を含むと理解される、 の化合物、R3及びR4が、これらが結合する炭素原子と共に、2−もしくは3− ピロリジン環、2−ピペリジン環、2−ピロリジン−5−オン環、または2−ア ザシクロヘプタン環を形成する式(I)の化合物の鏡像異性体及びジアステレオ 異性体、基−CO−CH=CH−COOR6を含んでいる式(I)の化合物のシ ス及びトランス異性体、並びにこれらの化合物の塩。 2.Hetが、場合によっては一つまたはそれより多いアルキル、フェニル、 カルボキシル、またはフェニルアルキル基で置換されたピロリル環、場合によっ ては一つまたはそれより多いアルキル、フェニル、カルボキシル、またはフェニ ルアルキル基で置換されたピリジル環、場合によっては一つまたはそれより多い アルキル、フェニル、カルボキシル、またはフェニルアルキル基で置換されたピ リミジニル環、場合によっては一つまたはそれより多いアルキル、フェニル、カ ルボキシル、またはフェニルアルキル基で置換されたイミダゾリル環、場合によ っては一つまたはそれより多いアルキル、フェニル、カルボキシル、またはフェ ニルアルキル基で置換されたチアゾリル環、場合によっては一つ、またはそれよ り多いアルキル、フェニル、カルボキシル、またはフェニルアルキル基で置換さ れたオキサゾリニル環、場合によっては一つまたはそれ より多いアルキル、フェニル、カルボキシル、またはフェニルアルキル基で置換 されたチアゾリニル環、場合によっては一つまたはそれより多いアルキル、フェ ニル、カルボキシル、またはフェニルアルキル基で置換されたピラジニル環、場 合によっては一つまたはそれより多いアルキル、フェニル、カルボキシル、また はフェニルアルキル基で置換されたテトラゾリル環、あるいは場合によっては一 つまたはそれより多いアルキル、フェニル、カルボキシル、またはフェニルアル キル基で置換されたトリゾリル環から選択される、請求の範囲1に記載の式(I )の化合物、及びこれらの塩。 3.Rが、水素原子、またはカルボキシル、アルコキシカルボニル、もしくは カルボキサミド基を表し、R1及びR2が水素またはハロゲン原子であり、そして R3及びR4が、これらが結合する炭素原子と共に、環が場合によってはその窒素 において、アルキル、−COOR11、−CO−alk−Ar”、−CO−NH− alk、−CO−NH−Ar”、−CO−alk、−alk−Ar”、−CO− alk−NR6R12、もしくは−CO−alk−COOR6で置換される2−もし くは3−ピロリジン環、または2−もしくは4−ピペリジン環、あるいは2−ピ ロリジン−5−オン環を形成する、請求の範囲1に記載の式(I)の化合物、及 びこれらの塩。 4.以下、 - (10’RS)−スピロ[ピロリジン−3,10’−5’H,10’H−イミ ダゾ[1,2−a]インデノ[1,2,−e]ピラジン]−4’−オン、 - (10’RS)−スピロ[ピペリジン−2,10’−5’H,10’ H−イミダゾ[1,2−a]インデノ[1,2,−e]ピラジン]−4’−オン 、 - (10’RS)−スピロ[ピロリジン−2,10’−5’H,10’H−イミ ダゾ[1,2−a]インデノ[1,2,−e]ピラジン]−4’−オン、 - (10’RS)−1−メチルスピロ[ピロリジン−2,10’−5’H,10 ’H−イミダゾ[1,2−a]インデノ[1,2,−e]ピラジン]−4’−オ ン、 - (+)−1−メチルスピロ[ピロリジン−2,10’−5’H,10’H−イ ミダゾ[1,2−a]インデノ[1,2,−e]ピラジン]−4’−オン、 - (−)−1−メチルスピロ[ピロリジン−2,10’−5’H,10’H−イ ミダゾ[1,2−a]インデノ[1,2,−e]ピラジン]−4’−オン、 - (10’RS)−4−オキソ−4−{4’−オキソ−4’,5’−ジヒドロス ピロ[ピロリジン−2,10’−10’H−イミダゾ[1,2−a]インデノ[ 1,2,−e]ピラジン−1−イル]}酪酸、 - スピロ[ピペリジン−4,10’−5’H,10’H−イミダゾ[1,2−a ]インデノ[1,2,−e]ピラジン]−4’−オン、 - 4−オキソ−4−{4’−オキソ−4’,5’−ジヒドロスピロ[ピペリジン −4,10’−10’H−イミダゾ[1,2−a]インデノ[1,2,−e]ピ ラジン−1−イル]}酪酸、 - 1−フェニルアセチルスピロ[ピペリジン−4,10’−5’H,10’H− イミダゾ[1,2−a]インデノ[1,2,−e]ピラジン] −4’−オン、 - 1−(メチルカルバモイル)スピロ[ピペリジン−4,10’−5’H,10 ’H−イミダゾ[1,2−a]インデノ[1,2,−e]ピラジン]−4’−オ ン、 - 1−メチルスピロ[ピペリジン−4,10’−5’H,10’H−イミダゾ[ 1,2−a]インデノ[1,2,−e]ピラジン]−4’−オン、 - 1−ベンジルスピロ[ピペリジン−4,10’−5’H,10’H−イミダゾ [1,2−a]インデノ[1,2,−e]ピラジン]−4’−オン、 - 1−フェニルスピロ[ピペリジン−4,10’−5’H,10’H−イミダゾ [1,2−a]インデノ[1,2,−e]ピラジン]−4’−オン、 - (10’RS)−1−アセチルスピロ[ピロリジン−2,10’−5’H,1 0’H−イミダゾ[1,2−a]インデノ[1,2,−e]ピラジン]−4’− オン、 - (10’RS)−1−[(3−メチルウレイド)アセチル]スピロ[ピロリジ ン−2,10’−5’H,10’H−イミダゾ[1,2−a]インデノ[1,2 ,−e]ピラジン]−4’−オン、 - (10’RS)−1−(フェニルカルバモイル)スピロ[ピロリジン−2,1 0’−5’H,10’H−イミダゾ[1,2−a]インデノ[1,2,−e]ピ ラジン]−4’−オン、 - (10’RS)−1−メチル−8’−フルオロスピロ[ピロリジン−2,10 ’−5’H,10’H−イミダゾ[1,2−a]インデノ[1, 2,−e]ピラジン]−4’−オン、 - (10’RS)−1−エチルスピロ[ピロリジン−2,10’−5’H,10 ’H−イミダゾ[1,2−a]インデノ[1,2,−e]ピラジン]−4’−オ ン、 - (10’RS)−1−プロピルスピロ[ピロリジン−2,10’−5’H,1 0’H−イミダゾ[1,2−a]インデノ[1,2,−e]ピラジン]−4’− オン、 - (10’RS)−4−オキソ−4−{4’−オキソ−4’,5’−ジヒドロス ピロ[ピロリジン−2,10’−10’H−イミダゾ[1,2−a]インデノ[ 1,2,−e]ピラジン−1−イル]}酪酸、 の化合物、及びこれらの塩。 5.式、 式中、Raはアミン官能基のための保護基を表し、そしてR、R1、及びR2は請 求の範囲1におけるものと同じ意味を有する、の誘導体を、式、 Hal−(CH2)p−Hal’ (III) 式中、同じまたは異なることができるHal及びHal’はハロゲン原子であり 、そしてpが3、4、または5に等しい、の誘導体と反応させ、 次にNHを脱保護し、その生成物を単離し、そして場合によってはそれを塩に転 化することを特徴とする、R3及びR4が、これらが結合する炭素原子と共に、2 −ピロリジン環、2−ピペリジン環、または2−アザシクロヘプタン環を形成す る請求の範囲1に記載の式(I)の化合物の調製方法。 6.N−n−ブトキシメチル−N−トリメチルシリルメチルベンジルアミンを 式、 式中、R、R1、及びR2は請求の範囲1におけるものと同じ意味を有する、の誘 導体と反応させ、次にNHを脱ベンジル化し、その生成物を単離し、そして場合 によってはそれを塩に転化することを特徴とする、R3及びR4が、これらが結合 する炭素原子と共に、3−ピロリジン環を形成する請求の範囲1に記載の式(I )の化合物の調製方法。 7.N,N−ビス(2−クロロエチル)−p−トルエンスルホンアミドを式、 式中、R、R1、及びR2は請求の範囲1におけるものと同じ意味を有する、の誘 導体と反応させ、次にスルホンアミド官能基を加水分解し、その生成物を単離し 、そして場合によってはそれを塩に転化することを特徴とする、R3及びR4が、 これらが結合する炭素原子と共に、4−ピペリジン環を形成する請求の範囲1に 記載の式(I)の化合物の調製方法。 8.式、 式中、Raはアセチル基を表し、R、R1、及びR2は請求の範囲1におけるもの と同じ意味を有する、の誘導体を3−ブロモプロピオン酸メチルと反応させ、そ の生成物を単離し、そして場合によってはそれを塩に転化することを特徴とする 、R3及びR4が、これらが結合する炭素原子と共に、2−ピロリジン−5−オン 環を形成する請求の範囲1に記載の式(I)の化合物の調製方法。 9.ホルムアルデヒド及びギ酸を、R3及びR4が、これらが結合する炭素原子 と共に、2−もしくは3−ピロリジン環、2−もしくは4−ピペリジン環、また は2−アザシクロヘプタン環を形成する式(I)の対応する化合物と反応させ、 その生成物を単離し、そして場合によってはそれを塩に転化することを特徴とす る、R3及びR4が、これらが結合する炭素原子と共に、窒素原子がアルキルIC 基で置換される2−もしくは3−ピロリジン環、2−もしくは4−ピペリジン環 、または2−アザシクロヘプタン環を形成する請求の範囲1に記載の式(I)の 化合物の調製方法。 10.ホウ水素化ナトリウムの存在下で、alkがアルキル1−5C基を表す 酸alk−COOHを、R3及びR4が、これらが結合する炭素原子と共に、2− もしくは3−ピロリジン環、2−もしくは4−ピペリジン環、または2−アザシ クロヘプタン環を形成する式(I)の対応する化合物と反応させ、その生成物を 単離し、そして場合によってはそれを塩に転化することを特徴とする、R3及び R4が、これらが結合する炭素原子と共に、窒素原子がアルキル(2−6C)基 で置換される2−もしくは3−ピロリジン環、2−もしくは4−ピペリジン環、 または2−アザシクロヘプタン環を形成する、請求の範囲1に記載の式(I)の 化合物の調製方法。 11.R3及びR4が、これらが結合する炭素原子と共に、2−もしくは3−ピ ロリジン環、2−もしくは4−ピペリジン環、または2−アザシクロヘプタン環 を形成する式(I)の対応する化合物を、式、 式中、Halはハロゲン原子を表し、そしてalkはアルキル基を表す、の誘導 体と反応させ、NH2を脱保護し、その生成物を単離し、そして場合によっては それを塩に転化することを特徴とする、R3及びR4が、これらが結合する炭素原 子と共に、R6及びR12が各々水素原子を表す基−CO−alk−NR6R12で窒 素原子が置換される2−もしくは3−ピロリジン環、2−もしくは4−ピペリジ ン環、または2−アザシクロヘプタン環を形成する請求の範囲1に記載の式(I )の化合物の調製方法。 12.R3及びR4が、これらが結合する炭素原子と共に、2−もしくは3−ピ ロリジン環、2−もしくは4−ピペリジン環、または2−アザシクロヘプタン環 を形成する式(I)の対応する化合物を、Halがハロゲン原子を表し、Rcが アルキル(2−6C)、−COOR11、−alk−Het、−alk−NR6R8 、−alk−COOR6、−alk−Ar”、−CO−alk、−CO−alk −COOR6、−CO−alk−NR6R12、もしくは−CO−COOR6基、ま たはシクロアルキルが場合によっては2位においてカルボキシル、−CO−Ar ”、−CO−alk−Ar”、−CO−Het、−CO−alk−Het、−C O−N(alk)alk’、−SO2−alk、もしくは−SO2−Arで置換さ れる基−CO−シクロアルキル(3−6C)を表し、alk、alk’、Het 、R6、R8、R1l、R12、Ar、及びAr”が請求の 範囲1におけるものと同じ意味を有する、ハロゲン化物Hal−Rcと反応させ 、その生成物を単離し、そして場合によってはそれを塩に転化することを特徴と する、R3及びR4が、これらが結合する炭素原子と共に、窒素原子がアルキル( 2−6C)、−COOR11、−alk−Het、−alk−NR6R8、−alk −COOR6、−alk−Ar”、−CO−alk、CO−alk−COOR6、 −CO−alk−NR6R12、もしくは−CO−COOR6基、またはシクロアル キルが場合によっては2位においてカルボキシル、−CO−Ar”、−CO−a lk−Ar”、−CO−Het、−CO−alk−Het、−CO−N(alk )alk’、−SO2−alk、もしくは−SO2−Ar基で置換される基−CO −シクロアルキルで置換される2−もしくは3−ピロリジン環、2−もしくは4 −ピペリジン環、または2−アザシクロヘプタン環を形成する請求の範囲1に記 載の式(I)の化合物の調製方法。 13.R3及びR4が、これらが結合する炭素原子と共に、窒素原子が基−CO −alk−COOR6または−alk−COOR6で置換される2−もしくは3− ピロリジン環、2−もしくは4−ピペリジン環、または2−アザシクロヘプタン 環を形成する式(I)の対応する化合物を、R6及びR8が請求の範囲1における ものと同じ意味を有するアミンHNR6R8と反応させ、その生成物を単離し、そ して場合によってはそれを塩に転化することを特徴とする、R3及びR4が、これ らが結合する炭素原子と共に、窒素原子が基−CO−alk−CONR6R8また は−alk−CO−NR6R8で置換される2−もしくは3−ピロリジン環、2− もしくは4−ピペリジン環、または2−アザシクロヘプタン環を形成する請求の 範囲1に記載の式(I)の化合物の調製方法。 14.R3及びR4が、これらが結合する炭素原子と共に、2−もしくは3−ピ ロリジン環、2−もしくは4−ピペリジン環、または2−アザシクロヘプタン環 を形成する式(I)の対応する化合物をCH3COOCHOと反応させ、その生 成物を単離し、そして場合によってはそれを塩に転化することを特徴とする、R3 及びR4が、これらが結合する炭素原子と共に、窒素原子が−CHO基で置換さ れる2−もしくは3−ピロリジン環、2−もしくは4−ピペリジン環、または2 −アザシクロヘプタン環を形成する請求の範囲1に記載の式(I)の化合物の調 製方法。 15.R3及びR4が、これらが結合する炭素原子と共に、2−もしくは3−ピ ロリジン環、2−もしくは4−ピペリジン環、または2−アザシクロヘプタン環 を形成する式(I)の対応する化合物を、Rdが基−CO−Het、−CO−a lk−COOR6、−CO−COOR6、−CO−alk−NR6R12、−CO− Ar”、−CO−alk−Ar”、−CO−alk−Het、もしくは−CO− alk、またはシクロアルキルが場合によっては2位においてカルボキシル基で 置換される基−CO−シクロアルキル(3−6C)を表し、Het、alk、R6 、R8、R12、Het、及びAr”が請求の範囲1におけるものと同じ意味を有 する誘導体HO−Rdと反応させ、その生成物を単離し、そして場合によっては それを塩に転化することを特徴とする、R3及びR4が、これらが結合する炭素原 子と共に、窒素原子が基−CO−Het、−CO−alk−COOR6、−CO −COOR6、−CO−alk−NR6R12、−CO−Ar”、−CO−alk− Ar”、−CO−alk−Het、もしくは−CO−alk、またはシクロアル キルが場合によっては2位においてカルボキシル基で置換される基−CO−シク ロアルキルで置換 される2−もしくは3−ピロリジン環、2−もしくは4−ピペリジン環、または 2−アザシクロヘプタン環を形成する請求の範囲1に記載の式(I)の化合物の 調製方法。 16.式、 式中、Aは、アルキル(直鎖の1−3C)、−CH2−C(CH3)2−CH2−、 −CH2-CH2−C(CH3)2−、−CH2−C(CH3)2−、−CH2−O−C H2−、−CH2−S−CH2−、または−CH=CH−を表し、Re及びRfは これらが結合する2個の炭素原子と共に、シクロアルキル(6C)、フェニル、 またはピリジル基を形成する、の無水物を、R3及びR4がこれらが結合する炭素 原子と共に、2−もしくは3−ピロリジン環、2−もしくは4−ピペリジン環、 または2−アザシクロヘプタン環を形成する式(I)の対応する化合物と反応さ せ、その生成物を単離し、そして場合によってはそれを塩に転化することを特徴 とする、R3及びR4が、これらが結合する炭素原子と共に、alkが直鎖で1な いし3個の炭素原子を含む基−CO−alk−COOR6、基−CO−CH2−C (CH3)2−CH2−COOR6、−CO−CH2−CH2−C(CH3)2−COO R6、−CO−CH2−C(CH3)2−COOR6、−CO−CH2−O−CH2− COOR6、−CO−CH2−S−CH2−COOR6、または−CO−CH=CH −COOR6、シクロアルキルが2位においてカルボキシル基で置換される基− CO−シクロアル キル(6C)、Ar”が2位においてカルボキシル基で置換されたフェニル基を 表す基−CO−Ar”、あるいは、Hetが3位においてカルボキシル基で置換 された2−もしくは4−ピリジル基または4位においてカルボキシル基で置換さ れた3−ピリジル基を表す基−CO−Hetで窒素原子が置換される2−もしく は3−ピロリジン環、2−もしくは4−ピペリジン環、または2−アザシクロヘ プタン環を形成し、そしてR6が水素原子を表す請求の範囲1に記載の式(I) の化合物の調製方法。 17.R3及びR4が、これらが結合する炭素原子と共に、2−もしくは3−ピ ロリジン環、2−もしくは4−ピペリジン環、または2−アザシクロヘプタン環 を形成する式(I)の対応する化合物を、Rgが酸素または硫黄原子を表し、R hがトリメチルシリル、アルキル、Het、−alk−Ar”、−alk−He t、またはAr”基を表し、Het、alk、及びAr”が請求の範囲1におけ るものと同じ意味を有する式Rg=C=N−Rhの誘導体と反応させ、その生成 物を単離し、そして場合によってはそれを塩に転化することを特徴とする、R3 及びR4が、これらが結合する炭素原子と共に、窒素原子が基−CO−NH−a lk−Ar”、−CO−NH−Het、−CO−NH−alk−Het、−CO −NH−Ar”、−CO−NH−alk、−CO−NH2、−CSNH2、−CS −NH−alk、−CS−NH−Ar”、または−CS−NH−Hetで置換さ れる2−もしくは3−ピロリジン環、2−もしくは4−ピペリジン環、または2 −アザシクロヘプタン環を形成する請求の範囲1に記載の式(I)の化合物の調 製方法。 18.R3及びR4が、これらが結合する炭素原子と共に、alkがア ルキル基を表し、そしてR6及びR12が各々水素原子を表す基−CO−alk− NR6−NR12で窒素原子が置換される2−もしくは3−ピロリジン環、2−も しくは4−ピペリジン環、または2−アザシクロヘプタン環を形成する式(I) の対応する化合物を、アルキルイソシアナートと反応させ、その生成物を単離し 、そして場合によってはそれを塩に転化することを特徴とする、R3及びR4が、 これらが結合する炭素原子と共に、R6が水素原子を表し、そしてR12が基−C O−NH−alkを表す基−CO−alk−NR6−NR12で窒素原子が置換さ れる2−もしくは3−ピロリジン環、2−もしくは4−ピペリジン環、または2 −アザシクロヘプタン環を形成する請求の範囲1に記載の式(I)の化合物の調 製方法。 19.Rがアルコキシカルボニル基を表す式(I)の対応する化合物を加水分 解し、その生成物を単離し、そして場合によってはそれを塩に転化することを特 徴とする、Rがカルボキシル基を表す請求の範囲1に記載の式(I)の化合物の 調製方法。 20.請求の範囲1に記載の式(I)の少なくとも一つの化合物を活性素とし て含んでいる医薬品。 21.請求の範囲2ないし4の一つに記載の式(I)の少なくとも一つの化合 物を活性素として含んでいる医薬品。 22.AMPA−レセプターのアンタゴニストとして有用な、請求の範囲17 及び18のいずれかに記載の医薬品。 23.NMDA−レセプターのアンタゴニストとして有用な、請求の範囲17 及び18のいずれかに記載の医薬品。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR94/13060 | 1994-11-02 | ||
FR9413060A FR2726275B1 (fr) | 1994-11-02 | 1994-11-02 | Spiro heterocycle-imidazo(1,2-a)indeno(1,2-e)pyrazine)-4'- ones, leur preparation et les medicaments les contenants |
PCT/FR1995/001430 WO1996014318A1 (fr) | 1994-11-02 | 1995-10-30 | SPIRO[HETEROCYCLE-IMIDAZO[1,2-a]INDENO[1,2-e]PYRAZINE]-4'-ONES, LEUR PREPARATION ET LES MEDICAMENTS LES CONTENANT |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH10508311A true JPH10508311A (ja) | 1998-08-18 |
Family
ID=9468413
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP8515088A Ceased JPH10508311A (ja) | 1994-11-02 | 1995-10-30 | スピロ[複素環−イミダゾ[1,2−a]インデノ[1,2−e]ピラジン]−4’−オン類、これらの調製、及びこれらを含んでいる医薬品 |
Country Status (12)
Country | Link |
---|---|
US (1) | US5777114A (ja) |
EP (1) | EP0789699B1 (ja) |
JP (1) | JPH10508311A (ja) |
AT (1) | ATE177747T1 (ja) |
AU (1) | AU3848595A (ja) |
DE (1) | DE69508421T2 (ja) |
DK (1) | DK0789699T3 (ja) |
ES (1) | ES2130669T3 (ja) |
FR (1) | FR2726275B1 (ja) |
GR (1) | GR3029714T3 (ja) |
WO (1) | WO1996014318A1 (ja) |
ZA (1) | ZA959044B (ja) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1436258A4 (en) * | 2001-03-08 | 2005-03-23 | Univ Emory | ANTAGONISTS OF THE NMDA RECEPTOR DEPENDENT OF PH |
US7045527B2 (en) | 2002-09-24 | 2006-05-16 | Amgen Inc. | Piperidine derivatives |
US7732162B2 (en) | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
MX2009004517A (es) * | 2006-10-30 | 2009-05-13 | Hybrigenics Sa | Nuevos inhibidores tetraciclicos de las proteasas de cisteina, las composiciones farmaceuticas de las mismas y sus aplicaciones terapeuticas. |
WO2008055945A1 (en) | 2006-11-09 | 2008-05-15 | Probiodrug Ag | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
ATE554085T1 (de) | 2006-11-30 | 2012-05-15 | Probiodrug Ag | Neue inhibitoren von glutaminylcyclase |
EP2481408A3 (en) | 2007-03-01 | 2013-01-09 | Probiodrug AG | New use of glutaminyl cyclase inhibitors |
EP2865670B1 (en) | 2007-04-18 | 2017-01-11 | Probiodrug AG | Thiourea derivatives as glutaminyl cyclase inhibitors |
EA201070077A1 (ru) * | 2007-06-29 | 2010-08-30 | Эмори Юниверсити | Антагонисты nmda-рецепторов с нейропротективным действием |
EP2475428B1 (en) | 2009-09-11 | 2015-07-01 | Probiodrug AG | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
EP2338492A1 (en) | 2009-12-24 | 2011-06-29 | Universidad del Pais Vasco | Methods and compositions for the treatment of alzheimer |
ES2586231T3 (es) | 2010-03-03 | 2016-10-13 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
CN102791704B (zh) | 2010-03-10 | 2015-11-25 | 前体生物药物股份公司 | 谷氨酰胺酰环化酶(qc, ec 2.3.2.5)的杂环抑制剂 |
EP2560953B1 (en) | 2010-04-21 | 2016-01-06 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
US8530670B2 (en) | 2011-03-16 | 2013-09-10 | Probiodrug Ag | Inhibitors |
PL3461819T3 (pl) | 2017-09-29 | 2020-11-30 | Probiodrug Ag | Inhibitory cyklazy glutaminylowej |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4354027A (en) * | 1980-05-19 | 1982-10-12 | Usv Pharmaceutical Corporation | Triazoloquinoxalin-4-ones |
DK101290D0 (da) * | 1990-04-24 | 1990-04-24 | Novo Nordisk As | Heterocykliske forbindelser, deres fremstilling og anvendelse |
FR2696466B1 (fr) * | 1992-10-02 | 1994-11-25 | Rhone Poulenc Rorer Sa | Dérivés de 5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazine-4-one, leur préparation et les médicaments les contenant. |
FR2707643B1 (fr) * | 1993-07-16 | 1995-08-11 | Rhone Poulenc Rorer Sa | Dérivés d'imidazo[1,2-a]pyrazine-4-one, leur préparation et les médicaments les contenant. |
-
1994
- 1994-11-02 FR FR9413060A patent/FR2726275B1/fr not_active Expired - Fee Related
-
1995
- 1995-10-25 ZA ZA959044A patent/ZA959044B/xx unknown
- 1995-10-30 JP JP8515088A patent/JPH10508311A/ja not_active Ceased
- 1995-10-30 US US08/836,410 patent/US5777114A/en not_active Expired - Fee Related
- 1995-10-30 AT AT95936624T patent/ATE177747T1/de not_active IP Right Cessation
- 1995-10-30 DE DE69508421T patent/DE69508421T2/de not_active Expired - Fee Related
- 1995-10-30 EP EP95936624A patent/EP0789699B1/fr not_active Expired - Lifetime
- 1995-10-30 ES ES95936624T patent/ES2130669T3/es not_active Expired - Lifetime
- 1995-10-30 WO PCT/FR1995/001430 patent/WO1996014318A1/fr active IP Right Grant
- 1995-10-30 AU AU38485/95A patent/AU3848595A/en not_active Abandoned
- 1995-10-30 DK DK95936624T patent/DK0789699T3/da active
-
1999
- 1999-03-18 GR GR990400113T patent/GR3029714T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
FR2726275A1 (fr) | 1996-05-03 |
EP0789699A1 (fr) | 1997-08-20 |
ES2130669T3 (es) | 1999-07-01 |
WO1996014318A1 (fr) | 1996-05-17 |
US5777114A (en) | 1998-07-07 |
DE69508421T2 (de) | 1999-07-15 |
DK0789699T3 (da) | 1999-10-11 |
ATE177747T1 (de) | 1999-04-15 |
ZA959044B (en) | 1996-05-22 |
EP0789699B1 (fr) | 1999-03-17 |
FR2726275B1 (fr) | 1996-12-06 |
GR3029714T3 (en) | 1999-06-30 |
DE69508421D1 (de) | 1999-04-22 |
AU3848595A (en) | 1996-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH10508311A (ja) | スピロ[複素環−イミダゾ[1,2−a]インデノ[1,2−e]ピラジン]−4’−オン類、これらの調製、及びこれらを含んでいる医薬品 | |
EP0708774B1 (fr) | DERIVES D'IMIDAZO[1,2-a]PYRAZIN-4-ONE ANTAGONISTES DES RECEPTEURS AMPA ET NMDA | |
EP2518067A1 (fr) | Dérives de N-[(1H-pyrazol-1-YL)aryl]-1H-indole ou 1H- indazole-3-carboxamide et leurs applications en thérapeutique comme antagonistes de P2Y12. | |
WO1995026342A1 (fr) | DERIVES DE 5H-INDENO[1,2-b]PYRAZINE-2,3-DIONE, LEUR PREPARATION ET LES MEDICAMENTS LES CONTENANT | |
AU623897B2 (en) | Indolyl and indazolyl cyclic amides | |
JPH09500123A (ja) | Ampaおよびnmda受容体の拮抗薬として有用なイミダゾ(1,2−a)ピラジン−4−オン誘導体 | |
US5807859A (en) | Imidazo (1,2-A)-Indeno (1,2-E) pyrazin-4-one derivatives and pharmaceutical compositions containing same | |
JP2007297411A (ja) | イミダゾ[1,2−a]インデノ[1,2−e]ピラジン−2−カルボン酸の誘導体、その製造およびそれを含む薬物 | |
JPH09510726A (ja) | インデノ[1,2−e]ピラジン−4−オン、その製造およびそれを含む医薬品 | |
JPH11511487A (ja) | インドリルマレイミドの合成 | |
WO1994007893A1 (fr) | DERIVES DE 5H,10H-IMIDAZO[1,2-a]INDENO[1,2-e]PYRAZINE-4-ONE, LEUR PREPARATION ET LES MEDICAMENTS LES CONTENANT | |
JPH09510730A (ja) | イミダゾ[1,2−a]ピラジン−4−オン誘導体、それらの製造及びそれを含む薬剤 | |
HU198937B (en) | Process for producing indolopyrazino benzodiazepine derivatives and pharmaceutical compositions comprising same | |
EP1492792B1 (fr) | Derives de 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino¬4,5-b|indole-1-acetamide,leur preparation et leur application en therapeutique | |
EP1922320A1 (fr) | Derives de 5-pyridazinyl-1-azabicyclo[3.2.1]octane, leur preparation et leur application en therapeutique | |
JPH06211844A (ja) | ベンゾフラン誘導体 | |
JPH10504027A (ja) | NMDA拮抗物質としての4−ヒドロキシ−3−フェニル−インデノ(1,2−b)ピリジン−2(1H)−オン誘導体類 | |
JPH11503144A (ja) | 5H,10H−イミダゾ[1,2−a]インデノ[1,2−e]ピラジン−4−オン誘導体、それらの製造法、およびそれらを含む医療薬 | |
JP2002507983A (ja) | (1h−イミダゾール−4−イル)ピペリジン誘導体、それらの製造およびそれらの治療における応用 | |
FR2772764A1 (fr) | Nouveaux inhibiteurs de farnesyle transferase, leur preparation, les compositions pharmaceutiques qui les contiennent et leur utilisation pour la preparation de medicaments | |
JPH09508408A (ja) | トリアゾール誘導体 | |
US5047402A (en) | Cyclic amides as medicaments | |
EP0752993A1 (fr) | DERIVES DE 1,2,4-TRIAZOLO [4.3-a] PYRAZINE-4-ONE, LEUR PREPARATION ET LES MEDICAMENTS LES CONTENANT |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20061017 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20061004 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070117 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070305 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070416 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070904 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071116 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20071221 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20080501 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080617 |